Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BCDA | US
0
0%
Healthcare
Biotechnology
30/06/2024
20/03/2026
1.20
1.22
1.23
1.16
BioCardia Inc. a clinical-stage regenerative medicine company engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform an investigational culture expanded bone marrow derived mesenchymal cell therapy which is in Phase I/II trial for the treatment of ischemic heart failure. In addition it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale California.
View LessLow Debt to Equity (< 0.25)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
51.4%1 month
56.3%3 months
57.1%6 months
72.9%-
-
10.67
-0.58
0.39
-3.16
20.90
-
-8.53M
4.20M
4.20M
-
-54.97K
-
-93.00
-703.62
0.22
4.06
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.27
Range1M
0.31
Range3M
0.34
Rel. volume
0.54
Price X volume
45.55K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Curis Inc | CRIS | Biotechnology | 0.7712 | 4.61M | 1.89% | n/a | -6039.91% |
| Brainstorm Cell Therapeutics Inc | BCLI | Biotechnology | 0.843 | 4.48M | n/a | -27.28% | |
| Enzon Pharmaceuticals Inc | ENZN | Biotechnology | 0.06 | 4.28M | 12.00 | 0.00% | |
| Immuron Limited | IMRN | Biotechnology | 0.703 | 4.27M | -0.85% | n/a | 1.37% |
| SNTI | SNTI | Biotechnology | 0.92 | 4.21M | 2.14% | n/a | 80.96% |
| Hiru Corporation | HIRU | Biotechnology | 0.0022 | 4.16M | -4.35% | n/a | 263.27% |
| Neurotrope Inc | NTRP | Biotechnology | 2.54 | 4.03M | 5.83% | n/a | 0.00% |
| Cyclerion Therapeutics Inc | CYCN | Biotechnology | 1.59 | 4.00M | 5.30% | n/a | 0.00% |
| Jaguar Health Inc | JAGX | Biotechnology | 0.4194 | 3.88M | 0.33% | 0.25 | 176.14% |
| NuCana plc | NCNA | Biotechnology | 1.65 | 3.71M | -3.51% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.3938 | 3.75M | 0.31% | n/a | 19.98% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.23 | 3.14M | n/a | 17.32% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.09 | 1.15M | -2.34% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.16 | - | Cheaper |
| Ent. to Revenue | 20.90 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 10.67 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 57.11 | - | Lower Risk |
| Debt to Equity | -0.58 | -1.23 | Expensive |
| Debt to Assets | 0.39 | 0.25 | Expensive |
| Market Cap | 4.20M | - | Emerging |